Search

The article presents a study that analyzes the effects of retrograde autologous priming (RAP) on the use of intraoperative packed red cell (PRC) or blood product transfusion. The study was conducted on patients who underwent coronary artery bypass grafting (CABG) for the first time. The results of the study show that the practise of RAP does not necessarily lessen RPG and other blood product transfusion requirements.

Summary Anaemia is increasingly prevalent in the United Kingdom. Despite recommendations to the contrary, many patients undergo cardiac surgery with undiagnosed and untreated anaemia. According to the World Health Organization definition, 1463/2688 (54.4%) patients undergoing cardiac surgery between 2008 and 2009 in our institution were anaemic. Compared with non-anaemic patients, anaemia was significantly associated with transfusion (791 (54.1%) vs 275 (22.4%), p < 0.001, OR (95% CI) 3.4 (2.8-4.1)), death (45 (3.1%) vs 13 (1.1%), p = 0.0005, OR 2.4 (1.2-4.5)), and prolonged ICU stay (287 (19.6%) vs 168 (13.7%) p < 0.001, OR 1.3 (1.0-1.6)). The prevalence of anaemia in this cohort is much greater than that previously reported. The cause of this excess is not clear. Pre-operative anaemia is a strong predictor of increased transfusion requirement, risk of ICU stay and death during cardiac surgery. The effect of increasing haemoglobin concentration therapeutically is not yet clear. [ABSTRACT FROM AUTHOR]

High resolution computed tomography (HRCT) of the temporal bone is performed routinely in the preoperative evaluation for cochlear implantation. The largest multicentre retrospective analysis of data was undertaken to compare the findings on HRCT with the surgical findings in an attempt to determine the accuracy of HRCT. Of the 1009 patients referred, 525 were scanned of whom 335 were implanted. As part of this study we were also able to identify both radiological and non-radiological reasons for rejection of patients for cochlear implantation, the commonest cause being adequate residual hearing. The accuracy of HRCT in predicting cochlear ossification was 94.6%, with a 100% specificity and a 71% sensitivity. Meningitis was the leading cause of cochlear ossification (44%). We conclude from this extensive multicentre study of both adult and paediatric patients that HRCT is accurate in predicting cochlear abnormality. In post-meningitic patients magnetic resonance imaging (MRI) may be a useful additional investigation. [ABSTRACT FROM AUTHOR]

Ten leading otolaryngological journals were reviewed with a view to detecting the UK contribution to the ENT literature from 1985 to 1994. From a total number of 12 293 publications studied 2414 (19.6%) papers were found to originate from British and Northern Irish otolaryngological departments, with the proportion of UK papers remaining at around 20% throughout the whole 10-year period. These papers were fully reviewed and the number of authors, paper type, names of authors and originating department recorded. Eleven departments were responsible for 50.2% of the total number of publications with the most prolific author being responsible for 2.5% (n = 60) of the total number of UK papers. Over the 10-year period, there has been a significant change towards the publication of more clinical research at the expense of pure laboratory research in these 10 journals (χ2 P < 0.001). There has also been a move towards multiple authorship (three or more co-authors) over the same period with fewer single-author papers (P < 0.001). [ABSTRACT FROM AUTHOR]

In recent years, programmes combining egg freezing with egg sharing – Freeze & Share (F&S) – have become available in UK clinics. However, no literature exists about the characteristics of women seeking free egg freezing in return for donating a portion of their eggs. The aim of this study was to describe the demographic and fertility profile of women enrolling in a Freeze & Share programme in the UK's largest egg bank. Retrospective cohort analysis of 165 women enrolling in London Egg Bank's (LEB) Freeze & Share programme between 2018-2023. Demographic and fertility markers, embryology parameters and clinical pregnancy (CP) rates were assessed. Median AMH was 28.40pmol/L, AFC was 24 and BMI was 22.92 kg/m2. Most F&S patients were single (70.13%) followed by cohabiting/married (25.97%) and divorced (3.90%). The majority of F&S patients were White (69.09%) followed by Asian (15.76%), Mixed-Ethnicity (5.46%), Other (5.45%) and Black (4.24%). A 94.55% had a university degree and 5.45% had a professional qualification/GCSEs. In total, 233 F&S cycles were completed. At egg retrieval, median patient age was 34, median total eggs retrieved per cycle was 19, of which median 14 were mature. Per cycle, the F&S patient kept a median of 8 MII eggs for own use and 7 MII eggs were donated to LEB. Overall, F&S patients underwent a median of 1 cycle and accrued a total of 10 MII eggs for own future use. Only 1 F&S patient has returned to use her frozen eggs. Survival rate was 100%, fertilisation rate 66.7% and embryo utilisation rate 100%. No embryo transfer (ET) has occurred. The donated portion of eggs from F&S cycles have been used in 120 egg recipient cycles. Median survival rate was 100%, fertilisation rate 71.43% and utilisation rate 50%. CP/fresh ET was 52.1% and CP/frozen ET was 40%. The typical F&S patient is in her early/mid-thirties, single, White, with a university degree. She will accrue 10 MII eggs for herself, which she is unlikely to use within 5 years. High success rates in egg recipients confirm the likely absence of harm to sharers' future chances of success with frozen-thawed eggs. [ABSTRACT FROM AUTHOR]

Purpose Around 2000 heart transplants are performed in Europe annually. Primary Graft Dysfunction(PGD) rates in Europe are among the highest in the world. The increasing use of marginal donor organs has been suggested as a potential cause. Novel techniques using ex-vivo normothermic perfusion have garnered increasing interest but incur a significant cost. We present a series of patients who underwent heart transplantation at our unit using a novel implantation technique to reduce PGD that is cost-effective and reproducible Methods The donor heart is removed from cold storage and placed in an ice slush basin on arrival to our unit. An aortic cross clamp is applied distal to the donor ascending aorta. An antegrade infusion of 600mls of cold blood cardioplegia is followed by cold oxygenated blood (4-6°C) to achieve a mean aortic root pressure of 60-70 mmHg. This continuous antegrade perfusion is maintained throughout the left atrium and aortic anastomosis with a left ventricular vent in situ. A warm cardioplegia hotshot is infused into the aortic root prior to removal of the recipient aortic cross-clamp. The remaining anastomoses are carried out in the usual fashion sequentially. We compared our experience with this method with the national UK cohort (2015-2016) of patients (Control Group). We performed multivariable logistic regression comparing the two cohorts with PGD as the primary outcome measure. Confounders adjusted for include donor age, recipient age and donor-recipient gender mismatch. Results 139 (71.6 %) patients were male. 46(18.6%) of the patients had ischemic cardiomyopathy. The odds ratio of PGD in the control group was 2.99 (95% CI 1.02- 8.75) when compared to the Extended Cooling. Conclusion This novel approach is associated with significant reductions in PGD rates post-transplantation likely due to the shorter warm ischemic time. Larger studies are needed to show differences after further adjustment for known confounders of PGD. We believe this novel technique is safe, cost-effective and reproducible. [ABSTRACT FROM AUTHOR]

Objective: We evaluated the clinical safety and performance of the ultrathin strut biodegradable polymer-coated Supraflex Cruz (Sahajanand Medical TechnologiesLtd., Surat, India) sirolimus-eluting stent (SES) in an all-comer patient population requiring coronary stent implantation., Study Design: The study was a prospective, observational, multicentre, single-arm registry., Study Settings: The study was conducted at 19 NHS Hospitals across the UK, from March 2020 to September 2021., Study Participants: A total of 1904 patients with symptomatic coronary artery disease (age ≥18 years) who underwent percutaneous coronary intervention with at least one Supraflex Cruz SES were enrolled., Primary and Secondary Outcomes Measure: The primary endpoint was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI) and clinically indicated target lesion revascularisation (CI-TLR), at 12 months. Safety endpoints were stent thrombosis, all-cause death and any MI. Prespecified subgroups analysis included patients with diabetes mellitus, bifurcation lesion, type B2/C lesion defined as per ACC/AHA (American College of Cardiology/American Heart Association) lesion classification and long coronary lesions (>20 mm)., Results: A total of 2973 Supraflex Cruz SES were implanted in 1835 patients (mean age: 65.20±11.03 years). Of these, 404 patients had diabetes mellitus (491 lesions), 271 had bifurcation lesions (293 lesions), 1541 had type B2/C lesions (1832 lesions) and 985 had long coronary lesions (>20 mm, 1139 lesions). Among the overall population, device success was achieved in 98.2% of lesions. TLF occurred in 12 (0.7%) patients (0.3% cardiac death, 0.2% TV-MI, 0.2% CI-TLR) at 30 days and in 43 (2.3%) patients (0.8% cardiac death, 0.8% TV-MI, 0.8% CI-TLR) at 12 months follow-up. The rate of definite stent thrombosis was 0.3% in the overall population at 12 months. The incidence of TLF and stent thrombosis was 6.2% and 1% in the diabetic, 1.8% and none in bifurcation lesion, 2.5% and 0.3% in type B2/C lesion, and 2.7% and 0.3% in long coronary lesions (>20 mm) subgroups, respectively. at 12 months follow-up., Conclusion: The S-FLEX UK-II registry confirms the clinical safety and performance of the ultrathin Supraflex Cruz SES in an all-comer population with complex coronary artery disease, demonstrating low rates of TLF and stent thrombosis., Trial Registration Number: ISRCTN39751665 (https://doi.org/10.1186/ISRCTN39751665)., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Research Question: What implications for policy and practice can be derived from outcomes and trends observed across 8 years of a surrogacy programme in two UK-regulated IVF centres (London, Cardiff)?, Design: Retrospective cohort study analysing surrogacy treatments undertaken between 2014 and September 2021., Results: Surrogacy continues to rise in popularity in the UK despite the inability of those supporting safe and professional practice to advertise to recruit surrogates. In two IVF centres regulated by the Human Fertilisation and Embryology Authority (HFEA), both the number of surrogacy treatments and the proportion of those undertaken on behalf of same-sex male intended parents increased year on year in the period studied. From a cohort of 108 surrogates, 71 babies were born to 61 surrogates (with five pregnancies ongoing) by February 2022. No statistically significant difference in live birth rates (LBR) was observed between the heterosexual couples and same-sex male couples. Sample sizes of single and transgender intended parents were too small (n < 5) to compare. The use of vitrified oocytes in surrogacy treatments has increased year on year, while fresh oocyte use has declined since peaking in 2019. There was no significant difference in LBR between fresh and vitrified oocyte usage across the cohort., Conclusions: The number of surrogacy treatments steadily increased, with clear evidence that the proportion of same-sex male couples accessing surrogacy is a major contributor to this growth. Vitrified/warmed oocyte use now outstrips the use of fresh oocytes in the surrogacy treatment cycles studied here. The results represent a strong basis for supporting the liberalization of regulatory reform expected to be introduced in the UK later in 2022., (Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Objective: To identify clinical and biochemical characteristics associated with 7- & 30-day mortality and intensive care admission amongst diabetes patients admitted with COVID-19., Research Design and Methods: We conducted a cohort study collecting data from medical notes of hospitalised people with diabetes and COVID-19 in 7 hospitals within the Mersey-Cheshire region from 1 January to 30 June 2020. We also explored the impact on inpatient diabetes team resources. Univariate and multivariate logistic regression analyses were performed and optimised by splitting the dataset into a training, test, and validation sets, developing a robust predictive model for the primary outcome., Results: We analyzed data from 1004 diabetes patients (mean age 74.1 (± 12.6) years, predominantly men 60.7%). 45% belonged to the most deprived population quintile in the UK. Median BMI was 27.6 (IQR 23.9-32.4) kg/m 2 . The primary outcome (7-day mortality) occurred in 24%, increasing to 33% by day 30. Approximately one in ten patients required insulin infusion (9.8%). In univariate analyses, patients with type 2 diabetes had a higher risk of 7-day mortality [p < 0.05, OR 2.52 (1.06, 5.98)]. Patients requiring insulin infusion had a lower risk of death [p = 0.02, OR 0.5 (0.28, 0.9)]. CKD in younger patients (<70 years) had a greater risk of death [OR 2.74 (1.31-5.76)]. BMI, microvascular and macrovascular complications, HbA1c, and random non-fasting blood glucose on admission were not associated with mortality. On multivariate analysis, CRP and age remained associated with the primary outcome [OR 3.44 (2.17, 5.44)] allowing for a validated predictive model for death by day 7., Conclusions: Higher CRP and advanced age were associated with and predictive of death by day 7. However, BMI, presence of diabetes complications, and glycaemic control were not. A high proportion of these patients required insulin infusion warranting increased input from the inpatient diabetes teams., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Llanera, Wilmington, Shoo, Lisboa, Jarman, Wong, Nizza, Sharma, Kalathil, Rajeev, Williams, Yadav, Qureshi, Narayanan, Furlong, Westall and Nair.)

Research Question: Do donor age, AMH, AFC, BMI and reproductive history predict response to ovarian stimulation? Do donor and recipient clinical markers and embryology parameters predict recipient pregnancy and live birth?, Design: Retrospective cohort study of 494 altruistic oocyte donors aged 18-35 years; 340 were matched to 559 recipients. Predictors of donor total oocyte yield and total mature oocyte yield were identified. Total and mature oocyte number were compared according to stratified donor AMH and age. Donor, recipient and embryology parameters predictive of recipient primary outcomes (clinical pregnancy and live birth) were identified., Results: Donor age and AMH predicted total oocyte yield (P = 0.030 and P < 0.001)) and total mature oocyte yield (P = 0.011 and P < 0.001). Donors aged 30-35 years with AMH 15-29.9 pmol/l had lower total oocyte yield (P = 0.004) and mature oocyte yield (P < 0.001) than donors aged 18-24 years. Up to an AMH threshold of 39.9 pmol/l, increasing AMH levels predicted higher total oocyte yield (<15 pmol/l versus 15-29.9 pmol/l, P = 0.001; 15-29.9 pmol/l versus 30-39.9 pmol/l, P < 0.001; 30-39.9pmol/l versus ≥ 40 pmol/l, P = 1.0) and mature oocyte yield (<15 pmol/l versus 15-29.9 pmol/l, P = 0.005; 15-29.9 pmol/l versus 30-39.9 pmol/l, P = 0.006; 30-39.9 pmol/l versus ≥40 pmol/l, P = 1.0). In recipients, the rate of transferrable embryos per oocytes received, fertilized and number of embryo transfers needed to achieve the primary outcome were predictors of cumulative clinical pregnancy (P = 0.011, P = 0.017 and P < 0.001) and live birth (P = 0.008, P = 0.012 and P < 0.001) rates. Recipient BMI (P = 0.024) and previous miscarriages (P = 0.045) were predictors of cumulative live birth rate. Donor age 18-22 years was associated with a lower incidence of recipient clinical pregnancy (P = 0.004) and live birth (P = 0.001) after the first embryo transfer versus donor age 23-29 years., Conclusions: Donor age and AMH are independent predictors of oocyte yield. Raised recipient BMI and history of miscarriages reduce cumulative live birth rates, which may be increased by selecting donors aged 23-29 years, instead of younger donors., (Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)

Aim: To present initial single-centre experience with the Flow Re-Direction Endoluminal Device, FRED., Materials and Methods: This was a retrospective study. All patients treated with FRED from October 2015 to April 2017 were included in the study. Details of the aneurysms, complications as well as follow-up results were recorded. A PubMed search was performed using the keywords "Flow Re-Direction Endoluminal Device", "FRED", "flow diverter", "FD", "FD Stent", "flow re-direction" and "flow redirection" and the results were reviewed and compared to the present authors., Results: A total of 21 patients with 25 aneurysms were analysed. No patient was lost to follow-up. At 6 months follow-up, 17 aneurysms (68%) were completely occluded, five had reduced flow, two had persistent flow and the remaining one showed increased flow. Two aneurysms from the reduced flow at 6 months had achieved complete occlusion at 1 year, raising the complete occlusion rate to 76%. Overall, 22/25 (88%) aneurysms were either occluded completely or had reduced flow at 1 year. The appearances of the other aneurysms were stable in subsequent follow-ups. Three complications were recorded (one haemorrhagic, two occlusive/thromboembolic). There was no mortality in the present study. The occlusion rate at University Hospital of Wales as well as the complication rate was comparable to other centres on published data., Conclusion: FRED is a safe and effective flow diverter, which can be used to treat complex aneurysms that would have been of higher risk and for which for conventional coiling would be ineffective or unsuitable., (Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)

The hub-and-spoke model was introduced in the National Health Service (NHS) with the goal of providing equitable access to health care for all. This study uses bilateral breast reduction (BBR) surgery to assess the success of this model in delivering equity of access for plastic surgery within a publicly funded health-care system. This study also assessed the effect of socioeconomic deprivation on patients seeking BBR. The hospital records were used to identify all patients who underwent BBR at the St. John's Hospital between 1996 and 2005 (N=1081). Patients living outside the catchment area were excluded. Realistic travel distances and times to the hospital and clinics were calculated using patients' postcodes and geographic information systems (GIS) network analysis. Carstairs deprivation scores were obtained for the residential postcode of each patient. The main findings of this study are (1) accessibility to a plastic surgery clinic is an important factor in determining whether an eligible female patient undergoes BBR and (2) most deprived parts of the catchment area accounted for a significantly greater proportion of patients., (Copyright 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.)